Last reviewed · How we verify

Palbociclib + Letrozole — Competitive Intelligence Brief

Palbociclib + Letrozole (Palbociclib + Letrozole) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CDK4/6 inhibitor and aromatase inhibitor. Area: Oncology.

phase 3 CDK4/6 inhibitor and aromatase inhibitor CDK4/6 and aromatase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Palbociclib + Letrozole (Palbociclib + Letrozole) — Pfizer. Palbociclib is a CDK4/6 inhibitor that blocks the cell cycle, while Letrozole is an aromatase inhibitor that reduces estrogen levels.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Palbociclib + Letrozole TARGET Palbociclib + Letrozole Pfizer phase 3 CDK4/6 inhibitor and aromatase inhibitor CDK4/6 and aromatase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CDK4/6 inhibitor and aromatase inhibitor class)

  1. Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Palbociclib + Letrozole — Competitive Intelligence Brief. https://druglandscape.com/ci/palbociclib-letrozole. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: